SCHEMBL6477198

SCHEMBL6477198

Cc1cc(Cc2ccc(C(=O)O)cc2)c(=O)n2nc(C#Cc3ccccc3)[nH]c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
KAT8 Q9H7Z6 1/20 0.38
DHODH Q02127 1/20 0.38
RXRA P19793 2/20 0.37
FFAR1 O14842 1/20 0.36
CHRM2 P08172 1/20 0.36
S1PR1 P21453 1/20 0.36
FPR1 P21462 1/20 0.36
FPR3 P25089 1/20 0.36
GPR183 P32249 1/20 0.36
APLNR P35414 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
GPR65 Q8IYL9 1/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
CHEK2 O96017 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489420 0.84 GRM4 (0.35) FFAR1FFAR4
SCHEMBL6490898 0.82 TSHR (0.37) TSHRKAT8RXRAFFAR1CHRM2
SCHEMBL6488680 0.81 TSHR (0.38) TSHRKAT8RXRAFFAR1CHRM2
SCHEMBL6486967 0.74 RXRA (0.38) TSHRKAT8RXRAFFAR1CHRM2
SCHEMBL6819023 0.71 MMP13 (0.38) LMNAPOLBMEN1KMT2AMMP13
SCHEMBL6490897 0.69 KDM5A (0.38) DHODHRXRAMEN1KMT2AMMP13
SCHEMBL6484092 0.69 MEN1 (0.38) TSHRFPR1MEN1KMT2AMMP13
SCHEMBL6483921 0.69 MAPT (0.45) LMNAPOLBMMP13
SCHEMBL6475676 0.68 MEN1 (0.39) TSHRFPR1MEN1KMT2AMMP13
SCHEMBL6476082 0.68 TSHR (0.37) TSHRKAT8RXRAFFAR1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 TSHR 4356/4885KAT8 2064/4885DHODH 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.